The combination of osimertinib and savolitinib, evaluated in the ongoing phase 2 SAVANNAH trial (NCT03778229) [32] and the phase 2 open-label ORCHARD trial (NCT03944772) [33], is also expected to be effective in EGFR-mutant NSCLC with MET amplification, while the combination of osimertinib and necitumumab is expected to be effective in EGFR-mutant NSCLC with EGFR amplification. Here, MET is linked to non-small cell lung carcinoma.